The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4950-4956

  Mohammad, Ramzi M ^a   Wall, Nathan R ^a   Dutcher, Julie A ^a   Al Katib, Ayad M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C ACTIVATOR; REGULATOR PROTEIN; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LARGE CELL LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FAILURE; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; LACTONES; LYMPHOMA, LARGE-CELL; MACROLIDES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; POLY(ADP-RIBOSE) POLYMERASES; PREDNISOLONE; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0034486490     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Epidemiology of non-Hodgkin’s lymphoma: Recent findings are guarding an emerging epidemic
2. Cancer statistics, 1998
3. New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes
4. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, Adriamycin, vincristine and prednisone (CHOP)
5. Cancer statistics, 2000
6. Comparison of second generation combination chemotherapeutic regimen (m-BACOD) with standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma
7. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma
8. The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: Achievements and caveats
9. Modeling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: Practical applications
10. Bryostatin 1 down-regulates mdrl and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenographs
11. Isolation and structure of bryostatin 1
12. Preclinical evaluation of bryostatin 1 as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity
13. The bryostatins
14. Bryostatin 1 induced modulation of the acute lymphoblastic leukemia cell line REH
15. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: Preclinical studies
16. Differential effects of bryostatin 1 on human non-Hodgkin’s B-lymphoma cell lines
17. Successful treatment of human Waldenstrom’s macroglobulinemia with combination biological and chemotherapy agents
18. Successful treatment of human chronic leukemia lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1
19. Advanced diffuse histiocytic lymphoma, a potentially curable disease: Results with combination chemotherapy
20. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
21. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression
22. Effects of Bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells
23. Clinical relevance of Bcl-2 overexpression in childhood acute lymphoblastic leukemia
24. Expression and regulation of bcl-2, bcl-xl, and bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia
25. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
26. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax
27. Dysregulation of apoptosis in non-Hodgkin’s lymphomas: Toward a molecular understanding of bcl-2
28. Bcl-2 and adenovirus E1B kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase